Status:
TERMINATED
The Effect of Sertindole on Sensory Gating and Cognition in Schizophrenic Patients
Lead Sponsor:
University of Zurich
Collaborating Sponsors:
University Hospital of Psychiatry, Department Neuropsychopharmacology and Brain Imaging
H. Lundbeck A/S
Conditions:
Schizophrenia
Eligibility:
All Genders
18-40 years
Phase:
NA
Brief Summary
This study aims to investigate whether the atypical antipsychotic and mixed 5-HT2/D2 antagonist sertindole modulates or improves both subcortical and cortical information processing in schizophrenic p...
Eligibility Criteria
Inclusion
- Schizophrenia according to DSM IV
- Selected and treated in respect of the SPC (20 mg Serdolect max. and population at risk will be excluded)
Exclusion
- DSM IV Axis I disorders other than schizophrenia: Substance-dependence (excepting nicotine-dependence and substance-abuse), recent (2 months) DSM IV diagnosis according to DIA-X of a major affective, anxiety disorder, eating-disorder.
- DSM IV Axis II disorders: Lifetime DSM IV diagnosis of personality disorder.
- ECG: QTc-interval \>450 msec.
- Systolic blood pressure \<100 mmHg
- Bradycardia (Hf \< 50/Min) und Arrhythmias
- Hypokalemia or Hypomagnesemia
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT00629252
Start Date
February 1 2008
End Date
August 1 2012
Last Update
September 17 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Psychiatry, Department Neuropsychopharmacology and Brain Imaging
Zurich, Canton of Zurich, Switzerland, CH-8032